London, Jan 28, 2026, 09:00 GMT — Regular session
GSK shares dropped 1.8% to 1,828.5 pence by mid-morning in London on Wednesday, pulling back after two days of gains. The stock was down 34 pence from Tuesday’s close, with roughly 951,000 shares changing hands, according to LSE data. (London South East)
GSK’s shares dipped after Monday’s announcement that the European Commission expanded approval for its RSV vaccine Arexvy to cover all adults aged 18 and up. The shot had already been greenlit in the EU for older adults and certain high-risk groups. RSV, which can lead to infections in the lower airways and lungs, poses a significant threat to adults, the company emphasized. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, head of vaccines R&D, in the filing. (SEC)
This is crucial because the vaccinated population’s size depends on national guidelines and funding, not simply a change in labeling. Investors are focused on whether European health agencies and governments act swiftly to translate broader approval into official guidance, purchase orders, and reimbursement plans before the upcoming RSV season this winter.
The FTSE 100 edged up roughly 0.1% in early trading. (Reuters)
GSK ended Tuesday up 1.9%, closing at 18.63 pounds, topping the FTSE 100’s 0.6% rise, MarketWatch data showed. (MarketWatch)
The race for RSV shots is heating up. Pfizer announced that the European Commission has broadened the approval for its RSV vaccine Abrysvo, now covering adults aged 18 to 59. This move adds another choice for policymakers across Europe. (Pfizer)
That said, having a broader label doesn’t ensure a smooth sales climb. Vaccination policies vary across countries, budgets may drag their feet, and demand usually follows how harsh the season turns out.
GSK is set to update investors on February 4, releasing its full-year and Q4 results at 0700 GMT, per the company’s schedule. (GSK)
This week, traders will watch closely for any follow-up from EU advisory bodies and major health ministries on RSV vaccination for working-age adults. Attention will also be on GSK to see if it signals any near-term demand trends when it reports next Wednesday.
